Autologous chondrocyte implantation for rheumatoid arthritis of the knee: a case report
© Kim et al; licensee Cases Network Ltd. 2009
Received: 1 March 2008
Accepted: 22 January 2009
Published: 3 April 2009
Although pharmacologic treatment remains the mainstay for treating rheumatoid arthritis, there is an increasing need for a method that biologically regenerates arthritic knee lesions as patient longevity continually increases.
We treated rheumatoid arthritis of the right knee in a 35-year-old female Korean patient using autologous chondrocyte implantation. Twelve months after surgery, the patient could walk without pain.
Autologous chondrocyte implantation appears to be effective for treating rheumatoid arthritis of the knee.
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. To date, pharmacologic treatment remains the primary form of treatment, however, if pain and limitation of joint function become severe and debilitating, surgical treatment should be considered . Over the last few decades, artificial joint replacement techniques have developed very rapidly and many arthritic conditions have thus been successfully treated . However, as total joint arthroplasty is not permanent, in some cases, revisional surgery is inevitable, especially for young patients . Therefore, there is an ever-increasing need for a method that biologically regenerates the arthritic lesion of the knee as patient longevity continually increases. This report presents the case of a 35-year-old woman with a painful, arthritic knee and her treatment using autologous chondrocyte implantation (ACI).
Autologous chondrocyte implantation was performed 6 weeks after her initial surgery when 48 × 106 chondrocytes had been cultured. Autologous chondrocytes were aseptically processed, suspended in sterile Dulbecco's Modified Eagles Medium (DMEM), and were supplied in single-use containers. Cell viability was greater than 97% before final packaging. Twelve months postoperatively, the lateral joint space of the knee had become wider (Figure 1d), and the patient could walk and otherwise function without pain.
In order not to overflow the margin, the dependent position of the defect site was maintained for 5 minutes. Flexion and extension motion of the knee was performed three to five times in order to check for any graft failure. The wound was then closed layer by layer.
The patient remained non-weight-bearing for 6 weeks postoperatively, then began bearing weight of approximately 10 to 15kg from the seventh post-surgical week, and gradually progressed to full weight-bearing at 12 weeks post-surgery. A range of motion exercises from 0° to 40° was started on the day following surgery using continuous passive motion (CPM) for 4 to 6 hours daily. After 1 week, the angle was increased by 5° per day. During this period, the quadriceps strengthening exercise and stretching of the hamstring and calf were continued.
RA is a systemic disease primarily affecting the synovium. When pharmacologic agents fail to control the inflammatory process of the synovium, symptomatic joint destruction begins. In addition, the surgical results have not been satisfactory for advanced disease which creates bony destruction .
Total joint replacement arthroplasty is the standard treatment for severe arthritis and deformity of the knee , but there is currently no successful treatment before the severe stage of RA. Many doctors simply prescribe medication and recommend that patients with knee pain wait until their symptoms increase to the point where total joint replacement arthroplasty becomes necessary.
The current indications for ACI do not include arthritis [6, 7], as the present technique using liquid type chondrocytes cannot cover an arthritic lesion. In addition, there are many difficulties using the periosteum  to cover the total condyle so that it is watertight in the arthritic knee, and there is a high risk for breaking down of the treated lesion and progression to arthritis.
If we use a carrier, these problems can be overcome. Fibrin sealants are biological adhesives that mimic the final step of the coagulation cascade. They are used to reduce blood loss and postoperative bleeding . In this patient, the fibrin can maintain the shape of the articulation approximately 5 minutes after injection, thus causing the cells to stay in the injected sites. Even if there is a defect along the chondral margin, fibrin helps to maintain the shape of the graft according to the articulation . The multiple holes perform important functions by increasing the adhesive force of the graft to the defect during knee motion. In general, 2mm-deep holes in a sclerotic joint do not cause bleeding, however, in order to prevent both the formation of fibrocartilaginous tissue  and detachment of the injected cell and fibrin mixture, bleeding control is very important. The mild valgus deformity of this patient's knee was not corrected intra-operatively in order to minimize the potential for postoperative morbidity, and, fortunately, the deformity was naturally corrected as the lateral joint space became wider (Figure 1d) Our patient's symptom improvement was presumably due to coverage of the arthritic joint as well as new cartilage formation.
Although, to date, our experience is limited to one patient, autologous chondrocyte implantation appears to be effective for treating rheumatoid arthritis of the knee.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Special thanks to Bonnie Hami, MA (USA) for editing this manuscript.
- American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 2002, 46: 328-346. 10.1002/art.10148.View ArticleGoogle Scholar
- Martin SD, Scott RD, Thornhill TS: Current concepts of total knee arthroplasty. J Orthop Sports Phys Ther. 1998, 28: 252-261.View ArticlePubMedGoogle Scholar
- Mulhall KJ, Ghomrawi HM, Scully S, Callaghan JJ, Saleh KJ: Current etiologies and modes of failure in total knee arthroplasty revision. Clin Orthop Relat Res. 2006, 446: 45-50. 10.1097/01.blo.0000214421.21712.62.View ArticlePubMedGoogle Scholar
- Doets HC, Bierman BT, Soesbergen RM: Synovectomy of the rheumatoid knee does not prevent deterioration. 7-year follow-up of 83 cases. Acta Orthop Scand. 1989, 60: 523-525. 10.3109/17453678909150115.View ArticlePubMedGoogle Scholar
- Pandit H, Aslam N, Pirpiris M, Jinnah R: Total knee arthroplasty: the future. J Surg Orthop Adv. 2006, 15: 79-85.PubMedGoogle Scholar
- Yates JW: The effectiveness of autologous chondrocyte implantation for treatment of full-thickness articular cartilage lesions in workers' compensation patients. Orthopedics. 2003, 26: 295-300.PubMedGoogle Scholar
- Ferruzzi A, Calderoni P, Grigolo B, Gualtieri G: Autologous chondrocytes implantation: indications and results in the treatment of articular cartilage lesions of the knee. Chir Organi Mov. 2004, 89: 125-134.PubMedGoogle Scholar
- Chia SL, Gorna K, Gogolewski S, Alini M: Biodegradable elastomeric polyurethane membranes as chondrocyte carriers for cartilage repair. Tissue Eng. 2006, 12: 1945-1953. 10.1089/ten.2006.12.1945.View ArticlePubMedGoogle Scholar
- Mawatari M, Higo T, Tsutsumi Y, Shigematsu M, Hotokebuchi T: Effectiveness of autologous fibrin tissue adhesive in reducing postoperative blood loss during total hip arthroplasty: a prospective randomised study of 100 cases. J Orthop Surg. 2006, 14: 117-121.Google Scholar
- Ho W, Tawil B, Dunn JC, Wu BM: The behavior of human mesenchymal stem cells in 3D fibrin clots: Dependence on fibrinogen concentration and clot structure. Tissue Eng. 2006, 12: 1587-1595. 10.1089/ten.2006.12.1587.View ArticlePubMedGoogle Scholar
- Horas U, Pelinkovic D, Herr G, Aigner T, Schnettler R: Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint. A prospective, comparative trial. J Bone Joint Surg Am. 2003, 85: 185-192.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.